Bronchodilators in Anaphylaxis with Bronchospasm
Inhaled β2-agonist bronchodilators (such as nebulized albuterol 2.5-5 mg) are useful as adjunctive therapy specifically for bronchospasm that persists despite adequate doses of epinephrine in anaphylaxis, but they should never be used as first-line treatment or in place of epinephrine. 1
Treatment Algorithm for Anaphylaxis-Induced Bronchospasm
First-Line Treatment
- Epinephrine is the only first-line treatment for anaphylaxis, including when bronchospasm is present
- Intramuscular epinephrine should be administered immediately at the first recognition of anaphylaxis
- Epinephrine itself has bronchodilatory effects through β2-receptor stimulation
When to Add Bronchodilators
Bronchodilators are indicated only when:
- Bronchospasm persists or remains resistant after adequate doses of epinephrine have been administered 1
- The patient has received appropriate epinephrine but continues to have significant wheezing or respiratory distress
Specific Bronchodilator Regimen
When the above criteria are met:
- Nebulized albuterol 2.5 to 5 mg in 3 mL of saline
- Repeat as necessary based on clinical response 1
- This is considered second-line adjunctive therapy, not primary treatment
Critical Pitfalls to Avoid
Never Use Bronchodilators Alone
- β2-agonist bronchodilators should never be administered alone in anaphylaxis 2
- They do not address the underlying pathophysiology of anaphylaxis (mast cell and basophil mediator release)
- Delaying epinephrine to give bronchodilators first is associated with fatal outcomes 2
The Epinephrine Priority
The guideline evidence is unequivocal that epinephrine must come first 1. While bronchodilators are effective for bronchospasm in other contexts (such as asthma exacerbations, where they reduce hospitalizations 3), anaphylaxis is a multi-system emergency requiring immediate epinephrine for:
- Bronchodilation
- Vasoconstriction to reverse hypotension
- Decreased vascular permeability
- Decreased mediator release from mast cells and basophils
Clinical Context and Nuances
Why Bronchodilators Have a Role
Inhaled β2-agonists work through the same β2-adrenergic receptor mechanism as epinephrine but deliver higher local concentrations directly to the airways 4. When epinephrine alone doesn't fully resolve bronchospasm, adding nebulized albuterol provides:
- Additional direct bronchodilation
- Rapid onset (within 5 minutes) 5
- Effective airway smooth muscle relaxation 4
Positioning in the Treatment Hierarchy
The guideline clearly positions bronchodilators as fourth-line therapy after 1:
- Epinephrine (first-line)
- H1-antihistamines like diphenhydramine (second-line)
- H2-antihistamines like ranitidine (second-line, in combination with H1-antihistamines)
- Inhaled β-agonists for resistant bronchospasm (adjunctive)
Practical Implementation
In real-world emergency management:
- Give epinephrine immediately upon recognizing anaphylaxis
- Position patient supine (or in position of comfort if respiratory distress)
- Reassess respiratory status after epinephrine
- If wheezing persists despite adequate epinephrine dosing, then add nebulized albuterol
- Continue to repeat epinephrine every 5-15 minutes as needed while adding bronchodilator therapy
The evidence consistently shows that bronchodilators are valuable adjuncts for persistent bronchospasm in anaphylaxis, but only after epinephrine has been administered and only when bronchospasm remains refractory to epinephrine alone. 1, 2